CTOR
Citius Oncology, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.86
+8.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.1M | — | — | — | — |
| Cost of Revenue | 3.3M | — | — | — | — |
| Gross Profit | 3.8M | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.4M | 6.4M | 4.9M | 4.2M | 6.9M |
| SG&A Expense | 45.4M | 17.1M | 15.6M | 7.9M | 2.9M |
| General & Admin Expense | 37.6M | 17.1M | 15.6M | 7.9M | 2.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.3M | — | — | — | — |
| Total Operating Expenses | 51.1M | 23.5M | 20.6M | 12.1M | 9.7M |
| Cost and Expenses | 54.4M | 23.5M | 20.6M | 12.1M | 9.7M |
| Operating Income (EBIT) | (47.3M) | (23.5M) | (20.6M) | (12.1M) | (9.7M) |
| Non-Operating | |||||
| Interest Income | 168.9K | 36.4K | — | — | — |
| Interest Expense | 547.4K | 218.0K | — | — | — |
| Net Interest Income | (378.5K) | (181.7K) | — | — | — |
| Other Non-Op Income/Expense | 1.4M | (181.7K) | — | — | — |
| Non-Operating Income (excl Interest) | (1.9M) | (36.4K) | — | — | — |
| EBT (Pre-Tax Income) | (45.9M) | (23.7M) | (20.6M) | (12.1M) | (9.7M) |
| Income Tax Expense | 189.9K | 1.1M | 576.0K | 576.0K | 1.2M |
| Bottom Line | |||||
| Net Income | (46.1M) | (24.8M) | (21.1M) | (12.7M) | (10.9M) |
| Earnings from Cont. Ops | (46.1M) | (24.8M) | (21.1M) | (12.7M) | (10.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (46.1M) | (24.8M) | (21.1M) | (12.7M) | (10.9M) |
| Per Share | |||||
| Basic EPS | ($0.48) | ($0.34) | ($0.30) | ($0.19) | ($0.08) |
| Diluted EPS | ($0.48) | ($0.34) | ($0.30) | ($0.19) | ($0.08) |
| Revenue Per Share | $0.07 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 107.9M | 73.3M | 71.6M | 89.5M | 90.2M |
| Diluted Shares Outstanding | 107.9M | 73.3M | 71.6M | 89.5M | 90.2M |
| Profitability Metrics | |||||
| EBITDA | (43.1M) | (23.5M) | (20.6M) | (12.1M) | — |
| D&A | 2.3M | — | — | — | 9.7M |
| EBIT | (45.4M) | (23.5M) | (20.6M) | (12.1M) | (9.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026